1 active not recruiting. 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 1 | Active not recruiting 1 |
Follow ALL: new trials by email Literature Review of ALL trials Research Report on ALL
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Venetoclax Plus Inotuzumab for B-ALL Venetoclax, Dexamethasone, Inotuzumab Ozogamicin - B-cell Acute Lymphoblastic Leukemia, B-Cell Lymphoma | Phase 1 | Active not recruiting | Dana-Farber Cancer Institute | 23 | 2021-09-24 | 2026-01-29 |
Burkitt Lymphoma (1) · Lymphoma, B-Cell (1)
DNA Virus Infections (1) · Epstein-Barr Virus Infections (1) · Hemic and Lymphatic Diseases (1) · Herpesviridae Infections (1) · Immune System Diseases (1) · Immunoproliferative Disorders (1) · Infections (1) · Lymphatic Diseases (1) · Lymphoma (1) · Lymphoma, Non-Hodgkin (1) · Lymphoproliferative Disorders (1) · Neoplasms (1) · Neoplasms by Histologic Type (1) · Tumor Virus Infections (1) · Virus Diseases (1)
Calcium Dobesilate (1) · Dexamethasone (1) · Inotuzumab Ozogamicin (1) · venetoclax (1)
Dana-Farber Cancer Institute (1)
United States (1)
Marlise R Luskin, MD, MSCE (1)